Recent Advances across Healthcare Biomarkers

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across healthcare biomarkers. Different biomarkers including blood-based proteomics and immuno-oncology biomarkers are profiled through recent innovations.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Healt

Table of Contents

Recent Advances across Healthcare BiomarkersRecent Advances across Healthcare BiomarkersBlood-based Proteomics for Breast Cancer DetectionRegulatory Approval for Biomarker-based Cancer Immunotherapy Combating Drug Resistance in OncologyBlood-based Biomarker Assay for Fibromyalgia DetectionBiomarker Analysis and Industry InteractionsBiomarker Analysis Industry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.